Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

Zagazig University

Status and phase: Completed; Phase 2

Conditions: Warts

Treatments: Biological: Candida antigen

Study type: Interventional

Funder types: Other

Identifiers

NCT04399577

3140/23-10-2016

Details and patient eligibility

About

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

Full description

39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Enrollment: 39 patients

Sex: All

Ages: 9 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic multiple cutaneous

Exclusion criteria

• Hypersensitivity to Candida antigen
• Fever
• Immunosuppressive disorders
• Previous wart therapy in the last month

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

39 participants in 1 patient group

Wart Patients

Experimental group

Description:

Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions

Treatment:

Biological: Candida antigen